Ask about this productRelated genes to: MYD88 antibody
- Gene:
- MYD88 NIH gene
- Name:
- MYD88 innate immune signal transduction adaptor
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 3p22.2
- Locus Type:
- gene with protein product
- Date approved:
- 1997-12-23
- Date modifiied:
- 2019-04-23
Related products to: MYD88 antibody
Related articles to: MYD88 antibody
- Primary central nervous system lymphoma (PCNSL) is an uncommon and aggressive extranodal non-Hodgkin lymphoma confined to the central nervous system, including the brain, leptomeninges, spinal cord, and eyes. Although high-dose methotrexate-based induction remains the backbone of first-line therapy, long-term disease control remains challenging, particularly in older or frail patients and in those with relapsed or refractory disease. Recent genomic and multi-omics studies have reshaped the biological understanding of PCNSL by identifying recurrent alterations in MYD88, CD79B, PIM1, PRDM1, CDKN2A/B, HLA-related genes, B2M, CIITA, and immune checkpoint loci, which converge on B-cell receptor/Toll-like receptor signaling, NF-κB activation, immune evasion, and microenvironmental adaptation. These molecular insights have accelerated minimally invasive diagnostics, including targeted mutation assays, multigene circulating tumor DNA profiling, methylation-based approaches, and cytokine analysis in cerebrospinal fluid, vitreous humor, and aqueous humor. Targeted and immune-based therapies, including Bruton tyrosine kinase inhibitors, immunomodulatory agents, immune checkpoint inhibitors, mTOR inhibitors, and CD19-directed chimeric antigen receptor T-cell therapy, have shown variable degrees of clinical activity, particularly in relapsed or refractory disease. However, most evidence remains derived from early-phase trials, single-arm studies, retrospective cohorts, or small series, and treatment selection is not yet routinely biomarker-defined. This review summarizes current advances in molecular taxonomy, pathogenesis, diagnostic work-up, liquid biopsy, prognostic stratification, and therapeutic management of PCNSL, emphasizing how molecular and longitudinal biomarker data may inform individualized treatment and future clinical trial design. - Source: PubMed
Publication date: 2026/07/29
Yan FengShan YongzhiFan XiaotongWang YamingWei PenghuZhao YongruiGuo Yixian - The bark, resin, and roots of (A. Rich.) Engl. have traditionally been used in African medicine to treat fever, stomach disorders, colic, and swelling. However, despite this traditional use, its anti-inflammatory activity and the underlying molecular mechanisms remain poorly characterized. - Source: PubMed
Mou CanglangWang YuhaoHuang LeiSu JinghanYou LongHe ZiliangHu YeyeWei WeizhaoleChoi WooramLee Byoung-HeeBang Woo YoungByun Hye-WooLee JongsungKim Ji HyeCho Jae Youl - Previous research has highlighted aerobic exercise as beneficial for patients with pulmonary hypertension (PH) and it is often recommended as a key therapeutic approach. However, the specific mechanisms behind these benefits are not yet fully understood. - Source: PubMed
Publication date: 2026/09/29
Chen ZhuHe ZiyuLiu XiaohanChen YajieZhou QianhuiLiu ZhiChen FenglingHuang YujuanWang ChengmingBai ZhuojunGuo Yuan - Patellofemoral joint (PFJ) osteoarthritis (OA) is characterized by cartilage degeneration, subchondral bone remodeling, fat pad fibrosis, and chronic synovial inflammation. This study investigated the therapeutic effects of extracorporeal shockwave therapy (ESWT) applied to different anatomical targets in a rat PFJ OA model. - Source: PubMed
Publication date: 2026/08/24
Jhan Shun-WunWu Kuan-TingChou Wen-YiChen Po-ChengHuang Wen-ChiungCheng Jai-Hong - The TLR4/MyD88 signaling axis serves as a central hub linking microbial- and damage-associated molecular patterns to oncogenic inflammation. Upon ligand engagement, MyD88 orchestrates two major downstream branches, including the canonical NF-κB pathway, which drives transcriptional programs for cell survival, proliferation, angiogenesis, and metastasis, and the NLRP3 inflammasome, which amplifies IL-1β/IL-18 release and pyroptosis. While these branches have been extensively studied individually, their integrated roles and crosstalk remain underexplored in cancer. Recent advances show that NF-κB provides the essential signal 1 for NLRP3 priming, yet the two pathways exert cell-type- and tumor-stage-dependent, sometimes opposing effects on tumor progression, therapy resistance, and anti-tumor immunity. We highlight cancer-type and cell-type specificity, microbiome influences, and emerging therapeutic opportunities targeting TLR4, NF-κB, and NLRP3 individually or in combination. This unified framework positions the TLR4/MyD88 axis as a high-value target for precision oncology and underscores the need for pathway-selective inhibitors to harness its divergent outputs. - Source: PubMed
Publication date: 2026/09/28
Zaeifi DavoodJamialahmadi KhadijehKarimi Gholamreza